The e TuBer erculos culosis is Vacc ccin ine e Init itia - - PowerPoint PPT Presentation

The e TuBer erculos culosis is Vacc ccin ine e Init itia iativ ive e (TBVI)

Research and Innovation partnership to discover and develop new, safe and effective TB vaccines that are accessible and affordable for all people Non-profit foundation that creates an enabling environment for TB vaccine research and innovation

• TBVI and its R&D partners develop and move the most promising TB vaccine and

biomarker candidates through the pipeline.

• TBVI supports collaborative research to innovate and diversify the pipeline and TB vaccine

platforms. TBVI adds value by providing services:

• technical advice through Product and Clinical development teams
• project identification, development and management;
• resource mobilisation

TBVI works through the Global TB Vaccine Partnership (GTBVP) with global stakeholders to:

• strengthen Global and European cooperation and coordination
• identify and address gaps to move the field forward.

TBVI operating principles

To select/down select vaccine candidates in an objective and transparent manner and to use the available financial resources effectively:

• TBVI assesses and manages its portfolio based on criteria in its TB Vaccine

Development Pathway tool.

• It seeks to align its R&I activities with other global efforts, in particular with

partners in the Global TB Vaccine Partnership (GTBVP).

• TBVI and its R&D partners have developed over 50% of the current

candidates in the TB vaccine pipeline To act as a neutral and honest broker

• Ownership of vaccine candidates and biomarkers, and any intellectual

property rights remain with researchers and vaccine developers

• enables TBVI to act as a neutral party without conflict of interest among its

R&D partners, global stakeholders and funders.

• D through partnership is the philosophy and spirit of TBVI’s collaborative research efforts. The

TBVI R&D strategic directions and priorities are based on the scientific and strategic inputs of

20 years of continued R&I work

TBVI : highlights of areas of work/funding needs 2020-2021

Product development

• move current leading TB vaccine candidates and fast followers through the

pipeline Collaborative research and innovation

• innovate and diversify the TB vaccine and biomarker pipeline and TB vaccine

platforms

• develop and test alternative vaccine routes and delivery mechanisms
• develop and validate pre-clinical models; develop human challenge models
• develop next generation portfolio management tools; harness the power of

AI for TB vaccine and biomarker research and clinical trials Global and European Cooperation and Coordination

• continue to build European excellence and leadership in TB vaccine R&D
• strengthen and grow GTBVP